Stifel reiterates Hold on BioMarin stock, keeps $68 price target

Stifel kept BioMarin at Hold with a $68 price target versus the $55.27 share price, implying meaningful upside from current levels. The company also reported positive Phase 3 VOXZOGO data in hypochondroplasia, with annualized growth velocity improving by 2.33 cm/year vs. placebo at week 52 and no new safety signals. Investors are also watching second-quarter guidance on Galafold, PomOp, and FOLD-related cost synergies, alongside ongoing litigation risk tied to TransCon-CNP.

Analysis

BMRN is the clearest beneficiary here, but the bigger setup is not the headline clinical readout — it is the company’s transition from a single-asset commercial story to a cash-generative platform with optionality. If management can convert incremental product cash flows into a visible R&D pipeline and disciplined M&A, the multiple can de-rate from a mature orphan-drug profile back toward a growth-biotech framework over the next 6-12 months. The market is still likely underappreciating how much confidence a clean, durable growth asset can create for financing future early-stage transactions without meaningful dilution.

The relative loser is ASND, not because its franchise is broken, but because the competitive narrative has become more fragile at exactly the wrong moment. Any evidence of meaningful switching from an entrenched therapy to a newer entrant would likely be incremental and slow, but even low initial switching rates matter because they cap the peak-share assumptions embedded in the market’s long-duration model. The litigation overhang is the real catalyst cluster: an adverse determination would not just block one product path, it would likely reset partner willingness, physician adoption momentum, and investor confidence across the class for multiple quarters.

FOLD is a subtler second-order beneficiary if BioMarin is signaling confidence in monetizing ex-U.S. commercialization and cost synergies from the acquisition. That creates a validation loop for tuck-in M&A in rare disease, especially if BioMarin proves it can squeeze operating leverage out of acquired assets faster than the street expects. The contrarian point: the stock may already be discounting the positive trial data, but not the implication that the company has earned a higher reinvestment runway — and that is what can move the multiple, not another incremental efficacy update.

Key Decisions for Investors

• Long BMRN / short ASND as a 1-3 month pair trade into the August legal catalyst; target 10-15% relative outperformance for BMRN if litigation and adoption dynamics stay favorable, stop if ASND wins the key ruling or switching data turns clearly positive for ASND.
• Add to BMRN on pullbacks below recent trading range with a 6-12 month horizon; risk/reward improves if management uses the quarter to raise confidence on revenue targets and cost synergies, which could support multiple expansion beyond the current hold-level framing.
• Sell downside protection on BMRN via put spreads around the next update only if position size is already owned; implied vol should stay bid into guidance and legal dates, making premium capture attractive while preserving a defined downside floor.
• Avoid chasing FOLD outright; use it as a relative-value monitor for whether BioMarin is extracting acquisition synergies faster than peers. If BMRN re-rates on M&A execution, FOLD-like orphan platforms become better acquisition targets, but the timing is likely months rather than weeks.
• For ASND holders, reduce exposure or hedge with short-dated puts into the August event; the risk/reward is asymmetric because a favorable ruling may only preserve the status quo, while an adverse ruling could compress multiple and sentiment quickly.